Keytruda (Pembrolizumab) Receives Supplemental FDA Approval for Efficacy

On April 11, 2019, the U.S. Food and Drug Administration (FDA) granted a supplemental approval for Keytruda (pembrolizumab). This approval, designated BLA 125514 S-47, specifically pertains to an update regarding the drug's efficacy profile, as submitted by its sponsor, Merck Sharp Dohme.

Background

Pembrolizumab, marketed as Keytruda, is an established immunotherapy drug. It is developed by Merck Sharp Dohme. As a widely used oncology treatment, Keytruda has received multiple prior approvals for various cancer indications. Supplemental applications like this one typically build upon an existing Biologics License Application (BLA), indicating an expansion or modification to the drug's approved uses, dosing, or other label information. In this specific instance, the supplemental approval focuses on updates related to the drug's efficacy.

What this means

This supplemental FDA approval for Keytruda signifies an important update to the drug's efficacy information. While the specific details of the updated efficacy are not provided in the source data, such approvals generally reflect new clinical data supporting an expanded indication, a new patient population, or a refinement of existing efficacy claims for the drug. For clinicians, this means there is new FDA-reviewed information to consider regarding how pembrolizumab performs in treating specific conditions, potentially impacting treatment decisions and patient management strategies. This could involve changes to prescribing information, new data on patient response rates, or updated information on duration of response. Researchers and patient advocates can look to the FDA's detailed approval documents for the specifics of this efficacy update, which will provide the full context and implications for patient care.

Source

The information regarding this supplemental FDA approval for Keytruda (pembrolizumab) was obtained from the U.S. Food and Drug Administration (FDA) official database. The approval, identified as BLA 125514 S-47, was granted on April 11, 2019, and is accessible via accessdata.fda.gov. The sponsor for this application was Merck Sharp Dohme.